NTRK3 and gliosarcoma: In case 2, Oncomine Comprehensive v3 analysis of the local left frontal gliosarcoma recurrence detected an EML4:NTRK3 fusion, a CDKN2A/B loss and an MRE11A alteration of unknown significance.